Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
Arthrosi’s investigational gout treatment is currently being evaluated in global studies
Read More
Tag: Sobi
NICE recommends Sobi’s Doptelet to treat thrombocytopenia
Primary ITP is a rare autoimmune condition characterised by high platelet destruction
Read More
New data shows improved prophylactic effectiveness with Sobi’s Elocta
Annualised bleed rate among haemophilia A patients was significantly lower in real-world setting
Read More
Sanofi and Sobi present effective bleeding treatment
Data demonstrates that efanesoctocog alfa provides superior bleed protection
Read More
NICE recommends Sobi’s Kineret for first-line use in Still’s disease
Biologic therapy approved to treat systemic juvenile idiopathic arthritis and adult-onset Still’s disease
Read More
Sobi launches thrombocytopenia drug Doptelet in EU
Drug will be launched in the UK first
Read More
Sobi to refile Gamifant following CHMP rejection
The company’s peak sales forecast of more than $500 million remains unchanged
Read More
Successful Elocta bid should widen access to the drug in the UK
Through an agreement with the NHS and Sobi UK, people living with haemophilia A in the UK will have increased access to Elocta following a successful bid in the UK’s Haemophilia A Tender
Read More
US OKs first treatment for haemophagocytic lymphohistiocytos
US regulators have approved Swedish Orphan Biovitrum (Sobi) and Novimmune’s Gamifant as the first treatment for the rare disorder primary haemophagocytic lymphohistiocytosis.
Read More
Sobi secures NHS reimbursement for Ravicti
Rare disease group Swedish Orphan Biovitrum (Sobi) says it has gained NHS England reimbursement for Ravicti for long-term management of urea-cycle disorders (UCDs) in adults and children.
Read More
Sobi launches Kineret for AOSD, SJIA
Sobi UK and Ireland has announced the launch of Kineret across the country offering a new treatment option for Adult Onset Stills Disease (AOSD) and Systemic-Onset Juvenile Idiopathic Arthritis (SJIA).
Read More
EU regulators expand reach of Sobi’s Kineret
European regulators have expanded the scope of Sobi’s Kineret to include the treatment of Still’s disease, a rare, systemic, multi-organ, auto-inflammatory disorder that affects around 25,000 children and adults in the EU.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
